Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients in Complete Remission With High Risk to Relapse

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2017 by Boehringer Ingelheim
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT01690624
First received: September 13, 2012
Last updated: January 9, 2017
Last verified: January 2017
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: March 2019
  Estimated Primary Completion Date: March 2019 (Final data collection date for primary outcome measure)